Electromed (ELMD) Q3 2026 earnings summary

Executive summary

• Achieved 14th consecutive quarter of year-over-year revenue and profit growth, with Q3 FY 2026 net revenues of $18.6 million, up 18.4% year-over-year, driven by strong homecare and hospital market growth.

• Operating income rose 76% to $3.8 million (20.3% margin), and net income increased 58.8% to $3.0 million ($0.35 per diluted share).

• Demonstrates consistent double-digit organic revenue growth and expanding profitability, supported by a direct-to-patient model and broad payor coverage.

• Maintained a strong cash position of $17 million and working capital of $40 million, with no debt as of March 31, 2026.

• Focuses on airway management devices, notably the SmartVest® HFCWO system, targeting chronic lung diseases.

Financial highlights

• Net revenues grew 18.4% to $18.6 million in Q3 FY 2026; TTM net revenues reached $71.8 million as of March 31, 2026.

• Gross profit increased to $14.6 million (78.8% margin) for the quarter; TTM gross margin held steady at 78%.

• SG&A expenses rose 7.2% to $10.5 million, mainly due to higher sales headcount and compensation.

• Operating income for the quarter was $3.8 million (20.3% margin); TTM operating income was $13.1 million (18% margin).

• Cash provided by operations for TTM was $10.5 million; cash balance as of March 31, 2026, was $17 million.

Outlook and guidance

• Confident in sustaining double-digit revenue growth and expanded operating leverage as fiscal 2026 concludes.

• Expects continued improvement in gross margins and operating leverage as scale increases.

• Plan to add four to five additional sales reps in the next fiscal year to support growth.

• Ongoing investments in sales force and infrastructure are planned to support continued growth.

• Management expects current working capital and available credit to be sufficient for operational and capital needs for at least the next twelve months.